Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in IgE-ACPA Positive Rheumatoid Arthritis
2009-017306-36Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of omalizumab in rheumatoid arthritis (RA), sponsored by Leiden University Medical Center. Primary endpoint: Disease Activity Score 44 (DAS44) response. Started Aug 2010; status: active.
02
Drugs
omalizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-017306-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017306-36.